An experimental, individualized mRNA cancer vaccine developed by Moderna and Merck & Co. has met its primary endpoint in a pivotal Phase 3 clinical trial, successfully delaying disease recurrence and preventing the spread of high-risk melanoma following surgery, according to company announcements. Independent data monitors confirmed that the vaccine, known as intismeran autogene (also referred to as V940 or MRNA-4157), showed statistically significant improvements when combined with Merck’s established immunotherapy drug Keytruda, compared to Keytruda administered alone.
The trial success marks a major milestone for personalized cancer therapies, triggering a sharp surge in Moderna’s stock price following the announcement. Analysts from firms such as TD Cowen and Jefferies characterized the milestone as a landmark moment that could unlock billions of dollars in commercial potential for melanoma treatment alone, while expanding the platform’s reach into other difficult-to-treat malignancies.
How the Personalized mRNA Vaccine Works
Unlike traditional vaccines or generalized oncology treatments, intismeran is custom-manufactured for each individual patient based on the unique genetic fingerprint of their tumor. According to Dr. Lennard Lee, a consultant medical oncologist at the University of Oxford cited by The Independent, doctors first surgical remove a patient’s tumor and analyze the biopsy DNA for specific mutations.
These mutations generate abnormal proteins known as neoantigens, which serve as red flags for the immune system. The mRNA vaccine delivers precise instructions corresponding up to 34 selected neoantigens, training the patient’s T cells to recognize and attack cancer cells carrying those exact markers. When administered alongside Keytruda—pembrolizumab, an immunotherapy that releases the brakes on the immune response—the combination effectively highlights tumor cells and activates the body’s natural defense mechanisms to hunt them down.
Clinical Trial Design and Results in Melanoma
The Phase 3 trial, designated INTerpath-001, enrolled more than 1,000 patients with advanced, high-risk melanoma who had undergone surgical tumor removal. Participants received either a combination of the intismeran vaccine given across nine doses every three weeks alongside Keytruda, or Keytruda alone.
Prior Phase 2 data involving 157 patients demonstrated that the intismeran combination reduced the relative risk of disease recurrence or death by 44 percent compared to Keytruda alone, according to data reported by BioPharma Dive. Standard Keytruda monotherapy typically reduces recurrence risk by 43 percent compared to a placebo, establishing a high benchmark that the combination therapy successfully surpassed in advanced settings.
Expanding Trials to Lung, Kidney, and Bladder Cancers
Building on the success in skin cancer, Moderna and Merck have expanded their clinical evaluation of personalized mRNA vaccines into other solid tumors. Trials evaluating the technology in non-small cell lung cancer have advanced to the final Phase 3 stage, while studies targeting kidney and bladder cancers remain active in Phase 2.
Cancer experts note that these tumor types represent prime candidates for immune-based therapies because they are classified as “hot” tumors, meaning immune cells have already naturally infiltrated the microenvironment and can be successfully reactivated by targeted treatments. Investigators plan to present comprehensive data from the Phase 3 melanoma trial at an upcoming medical meeting.
Keep reading